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Background: EGFR gene mutation is independently associated 
with a favorable response in non–small-cell lung cancer (NSCLC) 
patients receiving epidermal growth factor receptor -tyrosine kinase 
inhibitors (EGFR-TKIs), regardless of sex or smoking history. 
Squamous cell carcinoma patients harboring EGFR mutations show 
a significantly worse response to EGFR-TKIs compared with adeno-
carcinoma patients. We hypothesized that the serum cytokeratin 19 
fragment (CYFRA 21-1) is associated with the efficacy of EGFR-
TKIs in EGFR-mutated NSCLC patients.
Methods: We retrospectively screened 160 NSCLC patients harbor-
ing EGFR mutations, who had received either gefitinib, or erlotinib 
between 1992 and 2011. Patients were screened for clinical charac-
teristics, the efficacy of EGFR-TKI, and tumor markers (carcinoem-
bryonic antigen [CEA]/CYFRA 21-1) at the initial diagnosis.
Results: Of 160 eligible patients treated with EGFR-TKIs, 77 
patients with high CYFRA 21-1 level (>2 ng/ml) showed signifi-
cantly shorter progression-free survival (PFS) than the 83 patients 
with normal CYFRA 21-1 level (median PFS, 7.5 versus 13.3 
months; p < 0.001). No significant difference in PFS was observed 
between the high-CEA group (>5 ng/ml) and the normal-CEA group 
(median PFS, 8.6 versus 11.2 months; p = 0.242). A multivariate 
analysis revealed that high CYFRA 21-1 level is independently asso-
ciated with PFS (hazard ratio, 1.27; p = 0.002). No significant dif-
ference in overall survival was observed between the high- and the 
normal-CYFRA 21-1 groups (median overall survival, 24.8 versus 
39.1 months; p = 0.104).
Conclusions: Patients with a high CYFRA 21-1 level have signifi-
cantly shorter PFS. CYFRA 21-1 is not a prognostic but a predictive 
marker of EGFR-TKI treatment in EGFR-mutated NSCLC patients.
Key Words: Cytokeratin 19 fragment, Epidermal growth factor 
receptor-tyrosine kinase inhibitor, Non–small-cell lung cancer.
(J Thorac Oncol. 2013;8: 892-898)
Lung cancer is the leading cause of cancer death world-wide. Non–small-cell lung cancer (NSCLC) accounts for 
approximately 85% of lung cancers.1 Chemotherapy alone, 
or in combination with other agents, can modestly improve 
lung cancer outcomes, but at the cost of significant toxicity 
to patients. In recent years, molecular-targeted therapies, such 
as epidermal growth factor receptor (EGFR) inhibitors, have 
gained attention for their potential to improve patient survival 
and reduce toxic side effects.2–4 The efficacy of EGFR-tyrosine 
kinase inhibitors (TKIs) in the treatment of NSCLC has been 
proven, especially in EGFR-mutation–positive patients, and 
the presence of EGFR mutations is known to predict the effi-
cacy of EGFR-TKIs.5–7
EGFR mutations are usually found in adenocarcinoma 
and rarely in other histologic subtypes.8–12 The incidence 
of EGFR mutations in squamous cell carcinoma (SCC) is 
reported to be approximately 5%,12–15 therefore, most SCC 
patients do not seem to benefit much from major advances in 
the development of EGFR-gene–targeted therapy. Moreover, 
a recent pooled analysis showed that nonadenocarcinoma 
patients harboring EGFR mutations have shorter progres-
sion-free survival (PFS) when treated with EGFR-TKIs com-
pared with patients with adenocarcinoma harboring EGFR 
mutations.16
Cytokeratin 19 fragment (CYFRA 21-1) is both a 
sensitive and specific tumor marker for NSCLC, especially 
for SCC.17–21 Shukuya et al.16 reported that SCC patients 
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harboring EGFR mutations exhibit lower response to EGFR-
TKIs. We, therefore, hypothesized that the serum CYFRA 
21-1 level is related to the efficacy of EGFR-TKIs in NSCLC 
patients harboring EGFR mutations. Carcinoembryonic 
antigen (CEA), recognized as a tumor marker for NSCLC, 
is also useful for the detection of adenocarcinoma, with 
approximately 60% sensitivity and 50% specificity for 
adenocarcinoma,22,23 whereas the sensitivity and specificity 
is approximately 25% to 40% and 25%, respectively, for 
squamous cell carcinoma.19,20 Moreover, the serum CEA 
level at diagnosis is a poor prognostic factor in lung cancer 
patients.23–25 The aims of our present study were: (1) to analyze 
the predictive and prognostic value of the serum CYFRA 21-1 
level in EGFR-mutant patients treated with EGFR-TKI; (2) to 
compare the significance of CYFRA 21-1 with that of another 
tumor marker, CEA; (3) to identify the indicative factors 
among these tumor markers and the clinical characteristics 
(i.e., age, sex, smoking history, performance status [PS], and 
histology) associated therein.
PATIENTS AND METHODS
Patients and EGFR Mutation Analysis
In this retrospective study, we screened the cases of 160 
EGFR-mutated advanced NSCLC patients treated with EGFR-
TKIs at the Institute of Biomedical Research and Innovation 
or the Kobe City Medical Center General Hospital (Japan), 
between 1992 and 2011. All patients with locally advanced 
(stage IIIB), metastasized (stage IV), or postsurgically relapsed 
NSCLC were confirmed for EGFR mutations and received 
either gefitinib 250 mg/d or erlotinib 150 mg/d orally (clini-
cal stage was determined by the 7th edition of tumor, node, 
metastasis classification). EGFR mutations were identified by 
the peptide nucleic acid–locked nucleic acid polymerase chain 
reaction clamp method. One hundred fifty-three patients har-
bored activated EGFR mutations (either exon 19 deletions or 
L858R in exon 21). The other seven patients had minor muta-
tions (1 with L861Q in exon 21, and 6 with G719X in exon 
18). Histologic subclassification was carried out according to 
the World Health Organization classification.26 A computed 
tomography scan was performed for tumor assessment within 
28 days before initiating treatment, and was repeated every 2 
to 3 months. All responses were defined according to Response 
Evaluation Criteria in Solid Tumors. Response was confirmed 
at least 4 weeks (for a complete or partial response) or 6 weeks 
(for stable disease) after the first documentation.
Measurement of Serum CEA 
and CYFRA 21-1 Levels
The serum CEA level was measured within 2 weeks 
before the initial diagnosis of NSCLC, by a commercial elec-
trochemiluminescence immunoassay on the ARCHITECT 
i2000SR system (Abbott Diagnostics, Tokyo, Japan). The 
serum CYFRA 21-1 level was measured simultaneously, by 
a commercial electrochemiluminescence immunoassay on the 
ElecSys 2010 system (Roche Diagnostics, Indianapolis, IN). 
The standard cutoff values for CEA and CYFRA 21-1 at our 
institutions are 5.0 ng/ml and 2.0 ng/ml, respectively.
Statistical Analysis
Statistical analyses were performed using the JMP sta-
tistical software program (9th version; SAS Institute Inc., 
Cary, NC) to compare patient characteristics and responses 
with EGFR-TKI treatment. Wilcoxon test was performed to 
compare serum CYFRA 21-1 levels between the two groups. 
Survival curves were estimated by the Kaplan–Meier method, 
and the differences between the two groups were compared 
with the log-rank test. Single-variable survival analyses were 
done by means of log-rank tests, and the multivariate regres-
sion was done with Cox’s proportional hazard regression 
model. The PFS was calculated from the date of initiation of 
EGFR-TKI treatment to, either the date of disease progres-
sion, or the date of last contact. The overall survival (OS) was 
defined as the interval from the date of initiation of EGFR-
TKI treatment to the date of death from any cause, or the last 
follow-up. All tests were two-sided, and a p value of less than 
0.05 was considered significant.
RESULTS
Patient Characteristics
The clinical characteristics of the 160 patients are 
shown in Table 1. Ninety-one patients (57%) were women and 
97 (61%) were never-smokers, with an age range of 33 to 90 
years (median, 67 years). Most patients had adenocarcinoma; 
only eight patients had SCC, and one had large-cell carcinoma. 
TABLE 1.  Characteristics of the 160 NSCLC Patients 
Harboring EGFR Mutations
Characteristics No. of Patients %
Age (yr) Median (range) 67 (33–90)
Sex
 Men 69 43.1
 Women 91 56.9
Smoking history
 Never 97 60.6
 Former / current 63 39.4
Histology
 Adenocarcinoma 151 94.4
 Squamous / large 8 / 1 5.0 / 0.6
PS
 0 71 44.4
 1 69 43.1
 2 16 10.0
 3–4 4 2.5
EGFR-TKI
 Gefitinib 132 82.5
 Erlotinib 28 17.5
EGFR mutation
 Exon 19 deletion 71 44.4
 L858R 82 51.2
 Othersa 7 4.4
aOne with L861Q in exon 21 and 6 with G719X in exon 18.
EGFR-TKI, epidermal growth factor receptor-tyrosine kinase inhibitor; PS, 
performance status.
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One hundred thirty-two patients received gefitinib 250 mg/d, 
and 28 patients were treated with erlotinib 150 mg/d. Fifty-
seven patients were treated with EGFR-TKI as a first-line 
therapy, 67 patients as a second-line therapy, and 36 patients 
as third-line or thereafter. Seventy-one patients (44%) had a 
PS of 0, 69 (43%) had a PS of 1, 16 (10%) had a PS of 2, and 
four (3%) had a PS of 3 to 4.
Serum CYFRA 21-1/CEA Levels and PFS
Of 160 eligible patients treated with EGFR-TKIs, 83 
patients showed serum CYFRA 21-1 level above the normal 
upper limit of 2.0 ng/ml at initial diagnosis. The serum CEA 
level in 89 patients at initial diagnosis was elevated (> 5.0 ng/
ml). At the time of analysis, the median follow-up time was 
32.5 months (range, 23.3–44.6 months). The median duration 
of PFS in patients with high- and normal-serum CYFRA 21-1 
level was 7.5 months (95% confidence interval [CI], 6.2–
9.1 months) and 13.3 months (95% CI, 10.6–18.2 months), 
respectively (p < 0.001; Fig. 1A). In addition, there was no 
significant difference in tumor responses between high- and 
normal-CYFRA 21-1 groups (response rate, 48.1% versus 
42.2%; p = 0.818). The median durations of PFS in the two 
groups of patients with high- and normal-serum CEA levels 
were 8.6 months (95% CI, 7.6–11.9 months) and 11.2 months 
(95% CI, 7.1–16.6 months), respectively (p = 0.242; Fig. 1B).
Serum CYFRA 21-1/CEA Levels and OS
As shown in Figure 2A, the median duration of OS 
in the patients with high- and normal-serum CYFRA 21-1 
levels were 24.8 months (95% CI, 20.3–36.5 months) and 
FIGURE 1.  Kaplan–Meier survival curves of progression-free survival (PFS) according to (A) serum cytokeratin 19 fragment 
(CYFRA) and (B) carcinoembryonic antigen (CEA) level. The median duration of PFS in patients with high- and normal serum 
CYFRA 21-1 level was 7.5 months (95% confidence interval [CI], 6.2–9.1 months) and 13.3 months (95% CI, 10.6–18.2 
months), respectively (p < 0.001).  The median durations of PFS in the two groups of patients with high- and normal-serum 
CEA levels were 8.6 months (95% CI, 7.6–11.9 months) and 11.2 months (95% CI, 7.1–16.6 onths), respectively (p = 0.242).
FIGURE 2.  Kaplan–Meier survival 
curves of overall survival accord-
ing to (A) serum cytokeratin 19 
fragment and (B) carcinoembry-
onic antigen level. Kaplan–Meier 
survival curves of postprogression 
survival according to (C) serum 
cytokeratin 19 fragment and (D) 
carcinoembryonic antigen level.
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37.8 months (95% CI, 26.4–52.7 months), respectively (p = 
0.104). The median duration of OS in patients with high- and 
normal-serum CEA level was 26.0 months (95% CI, 20.3–
36.5 months) and 39.0 months (95% CI, 26.5–61.3 months), 
respectively (p = 0.163; Fig. 2B). There was no significant 
difference in OS between the high-CYFRA 21-1 group and 
the normal-CYFRA 21-1 group (median OS, 24.8 versus 
37.8 months; p = 0.104; Fig. 2A). Moreover, postprogression 
survival ([PPS], calculated as OS minus PFS) was almost 
the same between the two groups (median PPS, 14.7 versus 
18.0 months; p = 0.655; Fig. 2C). As for CEA, no significant 
difference in PPS was shown between the high-CEA group 
and the normal-CEA group (median OS, 26.0 versus 39.0 
months; p = 0.163; Fig. 2B).
Impact of Serum CYFRA21-1/CEA 
Levels on the Efficacy of EGFR-TKI
To determine the predictive importance of clinical 
characteristics and the serum CYFRA 21-1/CEA level in the 
EGFR-mutant NSCLC patients treated with EGFR-TKIs, 
we performed a Cox proportional hazard regression analysis 
on the parameters listed in Table 2. The univariate analyses 
revealed that high-serum CYFRA 21-1 level (p < 0.001), SCC 
(p = 0.002), and poor PS (p = 0.001) were significant negative 
predictive factors for PFS. In addition, the multivariate analy-
ses (Table 3) demonstrated that high-serum CYFRA 21-1 
level (hazard ratio [HR], 1.27; 95% CI, 1.11–1.40; p = 0.002) 
was independently a significant predictive factor for PFS.
Impact of Serum CYFRA21-1/
CEA Levels on Survival
To determine prognostic variant factors, we also 
performed a Cox proportional hazard regression analysis 
on the parameters listed in Table 2. The univariate analyses 
showed that SCC (p = 0.002) and poor PS (p < 0.001) were 
significantly associated with shorter OS. The multivariate 
analyses (Table 3) demonstrated that PS (HR, 1.62; 95% CI, 
1.14–2.22; p = 0.009) alone was a prognostic factor for OS.
Eight SCC Patients Harboring EGFR Mutations
As shown in Table 2, the eight SCC patients harboring 
EGFR mutations had significantly shorter PFS than the non-
SCC patients harboring EGFR mutations (median PFS, 4.0 
months versus 10.2 months; p = 0.002). We compared serum 
CYFRA 21-1 levels between 151 adenocarcinoma patients 
and eight SCC patients. CYFRA 21-1 level was significantly 
higher in SCC patients (median, 5.6 ng/ml; 95% CI, 1.7–8.3) 
compared with adenocarcinoma patients (median, 2.1 ng/ml; 
95% CI, 1.7–2.4; p = 0.014). The four patients with highest 
CYFRA 21-1 levels did not respond to EGFR-TKIs (disease 
progression was confirmed within 2 months), whereas the 
remaining four patients with lower serum CYFRA 21-1 levels 
had much longer PFS (median PFS, 1.0 months versus 7.0 
months; p = 0.007; Table 4).
DISCUSSION
Our findings revealed that high-serum CYFRA 21-1 
level at initial diagnosis was related to shorter PFS of EGFR-
TKIs in patients with EGFR-mutated NSCLC. Several reports 
have demonstrated that high levels of CEA and CYFRA 21-1 
at baseline are correlated with worse OS in advanced NSCLC 
patients.27,28 In the previous study, CYFRA 21-1 was shown 
to be significantly more sensitive than CEA for predicting 
clinical outcome of NSCLC patients (HR, 1.3; p = 0.01).27 
Recently, it was found that the factors CYFRA 21-1 and 
change in CYFRA 21-1 were reliable markers for response 
to chemotherapy for NSCLC patients.29 To the best of our 
knowledge, no serum marker for EGFR-mutated NSCLC has 
been reported to predict the efficacy of EGFR-TKIs, and ours 
may be the first report that focused on predicting PFS and OS 
of EGFR-TKI treatment in NSCLC patients harboring EGFR 
mutations.
EGFR mutations occur most frequently in female, non-
smoking, East-Asian, and adenocarcinoma patients.30 Several 
reports have suggested that tumor molecular profiling may 
supersede these clinical selection factors for EGFR-TKI treat-
ment in NSCLC patients. EGFR mutation was reported to be 
independently associated with a favorable prognosis in gefi-
tinib-treated patients, regardless of sex or smoking history.31 
However, in a pooled analysis,16 gefitinib was less effective 
in nonadenocarcinoma NSCLC harboring EGFR mutations, 
than in adenocarcinoma harboring EGFR mutations.
TABLE 2.  Factors Associated with PFS and OS
Factor n Median PFS (mo) pa Median OS (mo) pa
Age (yr)
 ≥70 95 9.9 0.684 28.9 0.453
 <70 65 10.3 35.6
Sex
 Men 69 7.6 0.492 26.4 0.585
 Women 91 10.6 34.4
Smoking history
 Never 97 10.3 0.783 35.6 0.541
 Former / current 63 7.5 30.5
Histology
 Squamous 8 4.0 0.002 12.8 0.002
 Nonsquamous 152 10.1 35.6
PS
 0,1 140 10.3 <0.001 35.6 <0.001
 2–4 20 6.0 16.3
EGFR-TKI
 Gefitinib 132 10.0 0.367 34.4 0.485
 Erlotinib 28 8.3 23.5
CEA
 >5ng/ml 77 11.2 0.242 39.0 0.163
 ≤5ng/ml 83 8.6 26.0
CYFRA 21-1
 >2ng/ml 71 13.3 <0.001 39.1 0.104
 ≤2 ng/ml 89 7.5 24.8
aUnivariate analysis by log-rank test.
PFS, progression-free survival; OS, overall survival; PS, performance status; EGFR-
TKI, epidermal growth factor receptor-tyrosine kinase inhibitor; CEA, carcinoembryonic 
antigen; CYFRA 21-1, cytokeratin 19 fragment.
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Distinguishing adenocarcinoma from SCC has recently 
provided clinical benefits for treatment decisions, however, 
the histologic classification is solely based on small biopsy or 
cytologic specimens in most cases. Travis et al.32 mentioned 
the considerable limitation of the diagnosis based on a small 
biopsy sample, which occasionally leads to controversial 
diagnosis in NSCLC. They indicated that one major 
underlying problem is the inherent histologic heterogeneity 
that exists in a subset of NSCLC. Because of this inherent 
histologic heterogeneity in NSCLC, and because the structural 
features of SCC or adenocarcinoma differentiation are focal 
or not distinguishable in small biopsy or cytologic specimens, 
10% of SCCs, 14% of adenocarcinomas, and 50% of large-
cell carcinomas were misclassified on the basis of bronchial 
biopsies.33
CYFRA 21-1 is 40 kD acidic protein that is part of the 
cytoskeleton of epithelial cells.34 Increased CYFRA 21-1 is 
the result of not only cytokeratin release as a consequence of 
cell lysis, or necrosis, but also the generation of cytokeratin 
filament by activated protease in tumor cells.35 Some studies 
have shown that CYFRA 21-1 is both a sensitive and spe-
cific tumor marker for NSCLC, and especially for SCC.17–21 
The sensitivity and specificity of CYFRA 21-1 for SCC were 
reported to be 66.5% and 95%, respectively, making CYFRA 
21-1 a much better diagnostic marker than CEA, for SCC.20 It 
was reported that the serum CYFRA 21-1 level is associated 
with the efficacy of pemetrexed in nonsquamous NSCLC and 
may be a predictive marker for pemetrexed use.36 Considering 
histologic heterogeneity in NSCLC, we speculated that the 
serum CYFRA 21-1 level in pretreatment lung cancer patients 
proportionately represents the extent of the squamous com-
ponent in the lung tumor. This hypothesis can explain the 
difference in pemetrexed’s efficacy in nonsquamous NSCLC 
between normal- and high-CYFRA 21-1 groups, because SCC 
patients have been reported to respond more poorly to peme-
trexed therapy compared with adenocarcinoma patients.37–39 
Our study demonstrated the difference in EGFR-TKI treat-
ment efficacy in NSCLC harboring EGFR mutations between 
normal- and high-CYFRA 21-1 groups. In addition, our mul-
tivariate analysis revealed that high CYFRA 21-1 level was an 
independent negative predictive factor for PFS in the EGFR-
mutant NSCLC patients (HR, 1.27; 95% CI, 1.11–1.40), con-
forming to our speculation that the serum CYFRA 21-1 level 
is associated with the proportion of the squamous component 
in NSCLC. As the frequency of SCC is low in EGFR-mutated 
NSCLC, CYFRA 21-1 is a more valuable predictive marker 
for EGFR-TKI treatment than squamous histology.
Similar to the Shukuya et al.16 report the eight SCC 
patients harboring EGFR mutations in our study also had 
shorter PFS (median PFS, 4.0 months) than the adenocarci-
noma patients harboring EGFR mutations. The interesting 
point is that higher CYFRA 21-1 level was closely related 
to the worse efficacy of EGFR-TKI even among the SCC 
patients. The four patients with highest CYFRA 21-1 levels 
did not respond to EGFR-TKIs (disease progression was con-
firmed within 2 months), whereas the remaining four patients 
with lower serum CYFRA 21-1 levels had much longer PFS 
(Table 4). We observed a strong trend, in which high CYFRA 
TABLE 3.  Multivariate Analysis of PFS and OS
Factor
PFS OS
HR (95% CI) pa HR (95% CI) pa
PS (2–4 vs. 0,1) 1.21 (0.91–1.56) 0.189 1.62 (1.14–2.22) 0.009
EGFR-TKI (erlotinib vs. gefitinib) 1.17 (0.88–1.50) 0.268 1.21 (0.79–1.74) 0.367
CEA (>5 ng/ml vs. < 5 ng/ml) 0.99 (0.76–1.17) 0.918 1.13 (0.88–1.46) 0.352
CYFRA 21-1 (>2 ng/ml vs. < 2 ng/ml) 1.27 (1.11–1.40) 0.002 1.10 (0.85–1.41) 0.484
aMultivariate analysis by Cox proportional hazards model.
PFS, progression-free survival; OS, overall survival; HR, hazard ratio; CI, confidence interval; PS, performance status; EGFR-TKI, epidermal growth factor receptor-tyrosine 
kinase inhibitor; CEA, carcinoembryonic antigen; CYFRA 21-1, cytokeratin 19 fragment.
TABLE 4.  Eight Squamous Cell Carcinoma Patients Harboring EGFR Mutations
Age(yr) / Sex (M, W) CYFRA 21-1 (ng/ml) PFS (mo) Response to EGFR-TKI Mutation Status Specimen
56/M 23.5 1.6 PD Exon 19 deletion Core biopsy
75/M 8.3 0.9 PD L858R FNA
72/M 7.9 1.1 PD L858R Core biopsy
61/M 5.8 0.8 PD Exon 19 deletion FNA
67/M 5.4 6.4 PR Exon 19 deletion Core biopsy
66/W 4.0 7.5 SD Exon 19 deletion FNA
62/M 3.2 6.5 PR Exon 19 deletion FNA
59/M 1.7 17.4 SD L858R Core biopsy
The normal range of CYFRA 21-1, 0–2.0 ng/ml.
EGFR-TKI, epidermal growth factor receptor-tyrosine kinase inhibitor; CYFRA 21-1, cytokeratin 19 fragment; PFS, progression-free survival; PD, progressive disease; FNA, 
fine-needle aspiration; PR, partial response; SD, stable disease.
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21-1 level patients with SCC harboring EGFR mutations had 
significantly worse responses to EGFR-TKI (median PFS, 1.0 
months versus 7.0 months; p = 0.007).
In our data, longer PFS in the normal-CYFRA 21-1 
group did not directly translate into longer OS compared with 
the high-CYFRA 21-1 group. The reason may be that the PPS, 
after EGFR-TKI failure, was almost equal between the high- 
and normal-CYFRA 21-1 groups (shown in Fig. 2C). This 
indicates that the serum CYFRA 21-1 level is not a surrogate 
marker for the efficacy of systemic cytotoxic chemotherapies 
other than EGFR-TKIs in NSCLC patients harboring EGFR 
mutations.
Our study has some limitations. First, we retrospectively 
screened 195 consecutive EGFR-mutated NSCLC patients 
treated with EGFR-TKIs, and 35 patients were excluded from 
our study because their serum CYFRA 21-1 was not examined 
at the initial diagnosis. This may have led to selection bias. 
Second, the data for OS were premature, with approximately 
50% of the patients still alive, when reported. Third, it is uncer-
tain whether the serum CYFRA 21-1 level actually represents a 
rich squamous component in each patient. At least, in the litera-
ture with which we are familiar, it has not been proven molecu-
larly that serum circulating CYFRA 21-1 is associated with the 
existence and progression of lung SCC component. We demon-
strated, as a whole, a significant trend in which the efficacy of 
EGFR-TKIs in patients harboring EGFR mutations depends on 
the initial serum CYFRA 21-1 level, which may represent the 
presence of a squamous-rich component in NSCLC.
In conclusion, CYFRA 21-1 is a predictive, not a prog-
nostic, marker of PFS in NSCLC patients harboring EGFR 
mutations when treated with EGFR-TKIs. An NSCLC 
patient’s circulating CYFRA 21-1 level should be measured 
before EGFR-TKI treatment, and this level could be used as 
a clinically relevant marker in NSCLC patients with EGFR 
mutations. A prospective clinical trial is needed to test our 
present findings.
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